Guardant Health
GH
$16.07
Share price
-3.60%
Change (1 day)
-35.15%
Change (1 year)
Categories
Guardant Health is an American company developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors.
Guardant Health (GH) - P/B ratio
P/B ratio as of April 2024 : 12.8
According to Guardant Health
's latest financial reports the company has a price-to-book ratio of 12.8.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Guardant Health - P/B ratio (from 2018 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | 20.7 | -55.31% |
| 2022-12-31 | 46.3 | 193.7% |
| 2021-12-31 | 15.8 | 65.85% |
| 2020-12-31 | 9.50 | 9.84% |
| 2019-12-31 | 8.65 | 40.92% |
| 2018-12-31 | 6.14 | |
| 2017-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Neogen NEOG | 0.8210 | -93.58% | 🇺🇸 USA |
 Natera NTRA | 13.8 | 7.71% | 🇺🇸 USA |